Fineline Cube

Follow:
14778 Articles
Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China
CompanyDrug

Chinese ADCs from Escugen, Hansoh, and MediLink Therapeutics Eye Breakthrough Designations in China

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania
CompanyDeals

GSK Commits USD 800 Million to New State-of-the-Art Manufacturing Facility in Pennsylvania

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
CompanyDeals

ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
CompanyDeals

LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS

Zhuhai Beihai Biotech's Beizary Receives FDA Clearance for Multiple Cancer Indications
CompanyDrug

Zhuhai Beihai Biotech’s Beizary Receives FDA Clearance for Multiple Cancer Indications

BeiGene's PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option
CompanyDrug

BeiGene’s PD-1 Inhibitor Tevimbra Scores First US Prescription, Offers More Affordable Option

RemeGen's Telitacicept Receives Priority Review Status from China's CDE for gMG Treatment
CompanyDrug

RemeGen’s Telitacicept Receives Priority Review Status from China’s CDE for gMG Treatment

China's Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports
Policy / Regulatory

China’s Pharmaceutical Trade Reaches USD 147.491 Billion in First Three Quarters, Export Growth Outpaces Imports

RemeGen's Taixia Pu Gets CDE Nod for Potential New Indication in Advanced Gastric Cancer
CompanyDrug

RemeGen’s Taitaxipu Receives CDE Acceptance for New Indication Application in China

CompanyMedical Device

Shanghai MicroPort Initiates Pre-Marketing Clinical Study for Embolic Microspheres in Liver Cancer Treatment

Chongqing Zhifei Biological's Influenza Vaccine Application Accepted by China's Drug Evaluation Center
CompanyDrug

Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center

TheDerma's Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs
Company

TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs